ストックスクリーナーアプリを入手
32.61
0.22%
0.0957
前日終値:
$32.71
開ける：
$33.08
24時間の取引高:
10,572
Relative Volume:
0.02
時価総額：
$1.88B
収益：
-
当期純損益:
$-100.44M
株価収益率:
-15.18
EPS:
-2.1478
ネットキャッシュフロー:
$-105.32M
1週間 パフォーマンス:
-13.02%
1か月 パフォーマンス:
-15.56%
6か月 パフォーマンス:
-8.46%
1年 パフォーマンス:
-36.14%
1日の値動き範囲:
$32.34
$33.75
1週間の範囲:
$29.48
$37.76
52週間の値動き範囲:
$26.61
$66.38
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
名前
Structure Therapeutics Inc Adr
セクター
電話
(628) 229-9277
住所
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
GPCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| GPCR | 32.65 | 1.88B | 0 | -100.44M | -105.32M | -2.1478 |
| VRTX | 447.13 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.99 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.16 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.55 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-21 | 開始されました | JP Morgan | Overweight |
| 2024-04-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-07-27 | 開始されました | Piper Sandler | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | BMO Capital Markets | Outperform |
| 2023-02-28 | 開始されました | Guggenheim | Buy |
| 2023-02-28 | 開始されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | SVB Securities | Outperform |
すべてを表示
Structure Therapeutics Inc Adr (GPCR) 最新ニュース
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Assetmark Inc. Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
FY2024 Earnings Forecast for GPCR Issued By Lifesci Capital - Defense World
GPCRStructure Therapeutics Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan
Structure Therapeutics (NASDAQ:GPCR) Trading Down 8.9%Here's What Happened - MarketBeat
Structure Therapeutics to Present at Jefferies London Healthcare Conference | GPCR Stock News - StockTitan
GSA Capital Partners LLP Purchases Shares of 30,464 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Reports Strong Q3 2024 Results - TipRanks
Structure Therapeutics Advances Obesity Drug Trial, Reports $915M Cash Position | GPCR Stock News - StockTitan
Structure Therapeutics Launches Phase 2b Obesity Drug Trial, Expands Testing to Higher Doses | GPCR Stock News - StockTitan
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World
Is Viking Therepautics a Buy Now? - MSN
Oral Proteins and Peptides Market to Reach $28.17 Billion by 2031 As Revealed In New Report - WhaTech
Some of the Major Key Players in the oral proteins and peptides market are - InsightAce Analytic
Structure Therapeutics Inc. (NASDAQ:GPCR) Position Increased by abrdn plc - MarketBeat
Ballard Power Systems Inc (NASDAQ: BLDP) Has Great Upside Potential - Stocks Register
Is Structure Therapeutics Inc ADR (NASDAQ: GPCR) A Good Investment For New Investors Now? - Stocks Register
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
Biopharma Co. Can't Knock Ex-CFO's Bias Suit Out Of Court - Law360
Armata Pharmaceuticals Announces Structural Biology Publication - StockTitan
Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21 - Business Wire
Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $86.80 - MarketBeat
GPCR drugmaker Septerna amasses $288M in IPO - BioPharma Dive
Griffin Asset Management Inc. Acquires New Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR (GPCR) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Exchange Traded Concepts LLC Has $1.80 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR Inc. (GPCR) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Daily Progress: Structure Therapeutics Inc ADR (GPCR) Drop -1.39, Closing at 38.32 - The Dwinnex
Is Structure Therapeutics Inc ADR (GPCR) a threat to investors? - US Post News
Structure Therapeutics (NASDAQ:GPCR) Shares Down 2.7%Here's What Happened - MarketBeat
Structure Therapeutics Inc ADR: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Top investors say Structure Therapeutics Inc ADR (GPCR) ticks everything they need - SETE News
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch. - BioPharma Dive
Weight Loss Drugs Market Top Trends 2024-2031 - InsightAce Analytic
Market Recap Check: Structure Therapeutics Inc ADR (GPCR)’s Positive Finish at 40.50, Up/Down 0.30 - The Dwinnex
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? - Yahoo Finance
Structure Therapeutics (NASDAQ:GPCR) Shares Up 3.7%Here's What Happened - MarketBeat
The Manufacturers Life Insurance Company Buys 32,839 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR (GPCR) is a good investment, but the stock may be overvalued - US Post News
27,094 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Bank of Montreal Can - MarketBeat
35,700 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Renaissance Technologies LLC - Defense World
Marshall Wace LLP Raises Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
3 AI Stocks to Buy as Nvidia Sputters - InvestorPlace
Are Structure Therapeutics Inc ADR (GPCR) shares a good deal now? - US Post News
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety - Yahoo Finance
Structure Therapeutics (NASDAQ:GPCR) Trading 5.8% Higher - MarketBeat
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer - BioSpace
Nasdaq Global Select Market Composite Index (NQGS) QuotePress Release - The Globe and Mail
S&P 100 Index (OEX) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
Structure Therapeutics Inc Adr (GPCR) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):